In Situ-Forming Microparticles for Controlled Release of Rivastigmine: In Vitro Optimization and In Vivo Evaluation

Abstract

In this work, sucrose acetate isobutyrate (SAIB) and polylactic co-glycolic acid (PLGA) were used alone or in combination as a matrix-former (MF) to prepare long-acting injectable rivastigmine (RV) in situ-forming microparticles (ISM). RV-ISM were prepared by the emulsification of an internal phase, containing the drug and the matrix former(s), into an external oily phase containing a stabilizer. The statistical design, Central Composite Design (CCD), was adopted as a quality by design (QbD) approach to optimize the formulation of RV-ISM systems. The fabricated RV-ISM systems was designed to minimize the initial burst drug release and maximize the sustainment of RV release from the ISM and ease of injection. The influence of critical formulation variables such as the matrix-former to drug (MF/D) ratio and SAIB to PLGA (S/P) ratio in the internal phase with respect to critical quality attributes (CQAs), such as the percentage drug release within the first day (Q1), the time required for 50% drug release (T50%) and the rate of injection, were studied using the CCD. The optimal RV-ISM system with the highest desirability value (0.74) was predicted to have an MF/D ratio of 11.7:1 (w/w) and an S/P ratio of 1.64:1 (w/w). The optimal RV-ISM system was assessed for its release profile, injectability, rheological properties, morphology, effect on cell viability, tolerance to γ-sterilization and in vivo performance in male albino rabbits. In vitro release studies revealed that the optimal RV-ISM system released 100% of its drug content throughout a release period of 30 days with only 15.5% drug release within the first day (Q1) and T50% of 13.09 days. Moreover, the optimal system showed a high injection rate of 1.012 mL/min, pseudoplastic flow, uniform spherical globules with homogenous particle size, minimal cytotoxicity and high tolerability to γ-sterilization. In vivo pharmacokinetic (PK) studies revealed that the rate of absorption of RV from the optimal RV-ISM system was controlled compared to a drug solution following either intramuscular (IM) or subcutaneous (SC) injection. Furthermore, the optimal RV-ISM was found to follow flip-flop PK with poor correlation between in vitro release and in vivo findings. These findings suggest that the optimal RV-ISM is a promising tool to achieve a sustained release therapy for RV; however, further investigation is still required to optimize the in vivo performance of RV-ISM.

Graphene Oxide/Chitosan Injectable Composite Hydrogel for Controlled Release of Doxorubicin: An Approach for Enhanced Intratumoral Delivery

“…The model was statistically validated using p-value, multiple correlation coefficient (R 2 ), adjusted multiple correlation coefficient (R 2 -adj), predicted multiple correlation coefficient (R 2 -pred) and adequate precision. Model selection was based on maximized R 2 -adj and R 2 -pred and a signal-to-noise ratio greater than 4 [ 33 , 34 ]. Three-dimensional response surface plots showing the effect of the CMAs on the different responses were created by Design-Expert ® software for graphical evaluation of the results and determination of the degree of interactions between the independent variables.…”

Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs

“…Haider et al ( 2021) developed in situ extended-release depots in the form of microparticles as a novel approach to improve the efficacy and tolerance of rivastigmine [95]. The polymeric microparticles were prepared using sucrose acetate isobutyrate (SAIB), PLGA, N-methyl-2-pyrrolidinone (NMP), and Pluronic ® F-68 by the emulsification method.…”

Nor-LAAM loaded PLGA Microparticles for Treating Opioid Use Disorder

“…Furthermore, nor-LAAM (IC 50 =12 µM) is much less potent than LAAM (IC 50 =3 µM) and similar potency to methadone (IC 50 =10 µM) to inhibit human ether-a-go-go-related gene (hERG) channels associated with cardiac toxicity, indicating that nor-LAAM may represent an improved OUD treatment alternative to methadone and LAAM because of the wider therapeutic window [18]. Prior studies have shown that drug-loaded PLGA microparticles provide sustained drug release, easy parenteral administration, and are biocompatible/safe [19,20]. In the field of substance use disorder, PLGA polymers have been used and approved as marketed formulations like Vivitrol ® and Sublocade ® for alcohol and opioid dependence, respectively.…”